1
|
Shakel Z, Costa Lima SA, Reis S. Strategies to make human skin models based on cellular senescence for ageing research. Ageing Res Rev 2024; 100:102430. [PMID: 39032611 DOI: 10.1016/j.arr.2024.102430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 06/25/2024] [Accepted: 07/15/2024] [Indexed: 07/23/2024]
Abstract
Human skin ageing is closely related to the ageing of the whole organism, and it's a continuous multisided process that is influenced not only by genetic and physiological factors but also by the cumulative impact of environmental factors. Currently, there is a scientific community need for developing skin models representing ageing processes to (i) enhance understanding on the mechanisms of ageing, (ii) discover new drugs for the treatment of age-related diseases, and (iii) develop effective dermo-cosmetics. Bioengineers worldwide are trying to reproduce skin ageing in the laboratory aiming to better comprehend and mitigate the senescence process. This review provides details on the main ageing molecular mechanisms and procedures to obtain in vitro aged skin models.
Collapse
Affiliation(s)
- Zinaida Shakel
- LAQV, REQUIMTE, Faculty of Pharmacy, University of Porto, Portugal
| | - Sofia A Costa Lima
- LAQV, REQUIMTE, ICBAS, School of Medicine and Biomedical Sciences, University of Porto, Portugal.
| | - Salette Reis
- LAQV, REQUIMTE, Faculty of Pharmacy, University of Porto, Portugal
| |
Collapse
|
2
|
How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development. Handb Exp Pharmacol 2020. [PMID: 32894342 DOI: 10.1007/164_2020_374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/12/2023]
Abstract
Preclinical research struggles with its predictive power for drug effects in patients. The clinical success of preclinically approved drug candidates ranges between 3% and 33%. Regardless of the approach, novel disease models and test methods need to prove their relevance and reliability for predicting drug effects in patients, which is usually achieved by method validation. Nevertheless, validating all models appears unrealistic due to the variety of diseases. Thus, novel concepts are needed to increase the quality of preclinical research.Herein, we introduce qualification as a minimal standard to establish the relevance of preclinical models and test methods. Qualification starts with prioritizing and translating scientific requirements into technical parameters by quality function deployment. Qualified models use authenticated cells, which resemble the corresponding cells in humans in morphology and drug target expression. Moreover, disease models differ from normal models in the expression of relevant biomarkers. As a result, qualified test methods can discriminate effects of treatment standards and the effects of weakly effective or ineffective substances. Observer-blind readout, adequate data documentation, dropout inclusion, and a priori power studies are as crucial as realistic dosage regimens for qualified approaches. Here, we showcase the implementation of qualification. Adjusting the level of model complexity and qualification to three defined phases of preclinical research assures the optimal level of certainty at each step.In conclusion, qualification strengthens the researchers' impact by defining basic requirements that novel approaches must fulfill while still allowing for scientific creativity. Qualification helps to improve the predictive power of preclinical research. Applied to human cell-based models, qualification reduces animal testing, since only effective drug candidates are subjected to final animal testing and subsequently to clinical trials.
Collapse
|
3
|
Spagolla Napoleão Tavares R, Stuchi Maria-Engler S, Colepicolo P, Debonsi HM, Schäfer-Korting M, Marx U, Rigo Gaspar L, Zoschke C. Skin Irritation Testing beyond Tissue Viability: Fucoxanthin Effects on Inflammation, Homeostasis, and Metabolism. Pharmaceutics 2020; 12:pharmaceutics12020136. [PMID: 32033492 PMCID: PMC7076544 DOI: 10.3390/pharmaceutics12020136] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 01/27/2020] [Accepted: 01/31/2020] [Indexed: 12/22/2022] Open
Abstract
UV light catalyzes the ozone formation from air pollutants, like nitrogen oxides. Since ozone reacts with cutaneous sebum lipids to peroxides and, thus, promotes inflammation, tumorigenesis, and aging, even broad-spectrum sunscreens cannot properly protect skin. Meanwhile, xanthophylls, like fucoxanthin, proved their antioxidant and cytoprotective functions, but the safety of their topical application in human cell-based models remains unknown. Aiming for a more detailed insight into the cutaneous fucoxanthin toxicity, we assessed the tissue viability according to OECD test guideline no. 439 as well as changes in inflammation (IL-1α, IL-6, IL-8), homeostasis (EGFR, HSPB1) and metabolism (NAT1). First, we proved the suitability of our 24-well-based reconstructed human skin for irritation testing. Next, we dissolved 0.5% fucoxanthin either in alkyl benzoate or in ethanol and applied both solutions onto the tissue surface. None of the solutions decreased RHS viability below 50%. In contrast, fucoxanthin ameliorated the detrimental effects of ethanol and reduced the gene expression of pro-inflammatory interleukins 6 and 8, while increasing NAT1 gene expression. In conclusion, we developed an organ-on-a-chip compatible RHS, being suitable for skin irritation testing beyond tissue viability assessment. Fucoxanthin proved to be non-irritant in RHS and already showed first skin protective effects following topical application.
Collapse
Affiliation(s)
- Renata Spagolla Napoleão Tavares
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil; (R.S.N.T.); (H.M.D.); (L.R.G.)
| | - Silvya Stuchi Maria-Engler
- Clinical and Toxicological Analyses Department, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 748, Cidade Universitária, São Paulo, SP 05508-000, Brazil;
| | - Pio Colepicolo
- Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes, 748, Cidade Universitária, São Paulo, SP 05508-000, Brazil;
| | - Hosana Maria Debonsi
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil; (R.S.N.T.); (H.M.D.); (L.R.G.)
| | - Monika Schäfer-Korting
- Institute of Pharmacy (Pharmacology & Toxicology), Freie Universität Berlin, Königin Luise Str 2+4, 14195 Berlin, Germany;
| | - Uwe Marx
- TissUse GmbH, Oudenarder Str. 16, 13347 Berlin, Germany;
| | - Lorena Rigo Gaspar
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil; (R.S.N.T.); (H.M.D.); (L.R.G.)
| | - Christian Zoschke
- Institute of Pharmacy (Pharmacology & Toxicology), Freie Universität Berlin, Königin Luise Str 2+4, 14195 Berlin, Germany;
- Correspondence: ; Tel.: +49-30-838-56189
| |
Collapse
|